1 Key Insights
2 Report Introduction
3 Major Depressive Disorder Market Overview at a Glance
3.1 Market Share (%) Distribution of MDD in 2018
3.2 Market Share (%) Distribution of MDD in 2030
4 Executive Summary of Major Depressive Disorder
5 Disease Background and Overview
5.1 Introduction
5.2 Sign and Symptoms
5.3 Types
5.4 Causes
5.5 Pathophysiology of Depression
5.6 Genetic basis of MDD
5.7 Biomarkers
5.8 Diagnosis and severity
5.8.1 The Diagnostic and Statistical Manual of Mental Disorders (DSM)
5.8.1.1 DSM-IV-TR Criteria for MDD
5.8.1.2 DSM-V: Diagnostic Criteria
5.8.1.3 Differential Diagnosis
5.8.1.4 DSM-IV-TR Criteria for Major Depressive Disorder
5.8.1.5 Depression Rating Scale
5.8.1.6 Montgomery–Åsberg Depression Rating Scale (MADRS)
5.8.1.7 Depression Rating Scale (DRS)
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total 12 months Prevalent Patient Population of Major Depressive Disorder
6.3 The United States
6.3.1 12 Months Prevalent Cases of Major Depressive Disorder in the US
6.3.2 Gender-specific Prevalence of Major Depressive Disorder in the US
6.3.3 Severity-specific Cases of Major Depressive Disorder in the US
6.3.4 Relapse/Refractory Cases of Major Depressive Disorder in the US
6.4 EU5
6.4.1 Germany
6.4.1.1 12 Months Prevalent Cases of Major Depressive Disorder in Germany
6.4.1.2 Gender-specific Prevalence of Major Depressive Disorder in Germany
6.4.1.3 Severity-specific Cases of Major Depressive Disorder in Germany
6.4.1.4 Relapse/Refractory Cases of Major Depressive Disorder in Germany
6.4.2 France
6.4.2.1 12 Months Prevalent Cases of Major Depressive Disorder in France
6.4.2.2 Gender-specific Prevalence of Major Depressive Disorder in France
6.4.2.3 Severity-specific Cases of Major Depressive Disorder in France
6.4.2.4 Relapse/Refractory Cases of Major Depressive Disorder in France
6.4.3 Italy
6.4.3.1 12 Months Prevalent Cases of Major Depressive Disorder in Italy
6.4.3.2 Gender-specific Prevalence of Major Depressive Disorder in Italy
6.4.3.3 Severity-specific Cases of Major Depressive Disorder in Italy
6.4.3.4 Relapse/Refractory Cases of Major Depressive Disorder in Italy
6.4.4 Spain
6.4.4.1 12 Months Prevalent Cases of Major Depressive Disorder in Spain
6.4.4.2 Gender-specific Prevalence of Major Depressive Disorder in Spain
6.4.4.3 Severity-specific Cases of Major Depressive Disorder in Spain
6.4.4.4 Relapse/Refractory Cases of Major Depressive Disorder in Spain
6.4.5 United Kingdom
6.4.5.1 12 Months Prevalent Cases of Major Depressive Disorder in the UK
6.4.5.2 Gender-specific Prevalence of Major Depressive Disorder in the UK
6.4.5.3 Severity-specific Cases of Major Depressive Disorder in the UK
6.4.5.4 Relapse/Refractory Cases of Major Depressive Disorder in the UK
6.5 Japan
6.5.1 12 Months Prevalent Cases of Major Depressive Disorder in Japan
6.5.2 Gender-specific Prevalence of Major Depressive Disorder in Japan
6.5.3 Severity-specific Cases of Major Depressive Disorder in Japan
6.5.4 Relapse/Refractory Cases of Major Depressive Disorder in Japan
7 Treatment and Management
7.1 American Psychiatric Association: Guideline on the Treatment of Patients with Major Depressive Disorder
7.2 Major Depressive Disorder Treatment Guidelines in the US and Europe
7.3 Guidelines in Spanish SHN for the Management of Major Depression in Adults
7.4 Major Depressive Disorder Treatment Guidelines in Japan
7.5 Major depressive disorder – Clinical practice review
7.6 Treatment Options for Adults
7.7 Treatment Options for Children and Adolescents
7.8 Treatment Options for Late-Life (Older Adults)
7.9 Algorithm for the Management of Major Depressive Disorder
7.1 Algorithm for the Pharmacotherapy of MDD
8 Organizations contributing towards MDD
9 Patient Journey
10 Case Report
11 Marketed Therapies
11.1 Key cross competition – Marketed Drugs
11.2 Brintellix: Takeda Pharmaceuticals
11.2.1 Product Description
11.2.2 Regulatory Milestones
11.2.3 Clinical Development
11.2.4 Clinical Trials Information
11.2.5 Safety and Efficacy
11.2.6 Product Profile
11.3 Fetzima: Forest Laboratories
11.3.1 Product Description
11.3.2 Pharmacokinetics
11.3.3 Regulatory Milestones
11.3.4 Clinical Development
11.3.5 Clinical Trials Information
11.3.6 Safety and Efficacy
11.3.7 Product Profile
11.4 Rexulti: Otsuka Pharmaceuticals
11.4.1 Product Description
11.4.2 Pharmacokinetics
11.4.3 Regulatory Milestones
11.4.4 Clinical Development
11.4.5 Clinical Trials Information
11.4.6 Safety and Efficacy
11.4.7 Product Profile
11.5 SPRAVATO (Esketamine): Janssen Research & Development
11.5.1 Product Description
11.5.2 Regulatory Milestones
11.5.3 Clinical Development
11.5.4 Clinical Trials Information
11.5.5 Safety and Efficacy
11.5.6 Product Profile
12 Emerging Therapies
12.1 AXS-05: Axsome Therapeutics
12.1.1 Drug Description
12.1.2 Regulatory Milestones
12.1.3 Clinical Development
12.1.4 Clinical Trials Information
12.1.5 Safety and Efficacy
12.1.6 Product Profile
12.2 Travivo: Fabre-Kramer Pharmaceuticals
12.2.1 Drug Description
12.2.2 Regulatory Milestones
12.2.3 Clinical Development
12.2.4 Product Profile
12.3 SAGE-217: SAGE Therapeutics
12.3.1 Drug Description
12.3.2 Regulatory Milestones
12.3.3 Clinical Development
12.3.4 Clinical Trials Information
12.3.5 Safety and Efficacy
12.3.6 Product Profile
12.4 VRAYLAR (Cariprazine): Allergan/Gedeon Richter
12.4.1 Drug Description
12.4.2 Regulatory Milestones
12.4.3 Clinical Development
12.4.4 Clinical Trials Information
12.4.5 Safety and Efficacy
12.4.6 Product Profile
12.5 CTC-501: Chase Therapeutics
12.5.1 Drug Description
12.5.2 Regulatory Milestones
12.5.3 Clinical Development
12.5.4 Clinical Trials Information
12.5.5 Product Profile
12.6 LY03005: Luye Pharma
12.6.1 Drug Description
12.6.2 Regulatory Milestones
12.6.3 Clinical Development
12.6.4 Clinical Trials Information
12.6.5 Product Profile
12.7 MIN-202 (Seltorexant): Janssen Pharmaceuticals/Minerva Neurosciences
12.7.1 Drug Description
12.7.2 Regulatory Milestones
12.7.3 Clinical Development
12.7.4 Clinical Trials Information
12.7.5 Safety and Efficacy
12.7.6 Product Profile
12.8 REL-1017: Relmada Therapeutics
12.8.1 Drug Description
12.8.2 Regulatory Milestones
12.8.3 Clinical Development
12.8.4 Clinical Trials Information
12.8.5 Product Profile
12.9 PRAX-114: Praxis Precision Medicines
12.9.1 Drug Description
12.9.2 Clinical Development
12.9.3 Clinical Trials Information
12.9.4 Safety and Efficacy
12.9.5 Product Profile
12.1 PDC-1421: BioLite Inc
12.10.1 Drug Description
12.10.2 Regulatory Milestones
12.10.3 Clinical Development
12.10.4 Clinical Trials Information
12.10.5 Product Profile
12.11 PH10: VistaGen Therapeutics
12.11.1 Drug Description
12.11.2 Mechanism of Action
12.11.3 Regulatory Milestones
12.11.4 Safety and Efficacy
12.11.5 Product Profile
12.12 AV-101: VistaGen Therapeutics
12.12.1 Drug Description
12.12.2 Regulatory Milestones
12.12.3 Clinical Development
12.12.4 Clinical Trials Information
12.12.5 Product Profile
12.13 CAPLYTA (Lumateperone): Intra-Cellular Therapies
12.13.1 Drug Description
12.13.2 Clinical Development
12.13.3 Clinical Trials Information
12.13.4 Product Profile
13 Discontinued Therapies
13.1 Pimavanserin: Acadia Pharmaceuticals
13.1.1 Drug Description
13.1.2 Mechanism of Action
13.1.3 Clinical Development
13.1.4 Clinical Trials Information
13.1.5 Product Profile
13.2 Rapastinel: Naurex (Allergan)
13.2.1 Drug Description
13.2.2 Regulatory Milestones
13.2.3 Clinical Development
13.2.4 Clinical Trials Information
13.2.5 Safety and Efficacy
13.2.6 Product Profile
14 No Development Reported
14.1 ALKS 5461: Alkermes
14.1.1 Drug Description
14.1.2 Regulatory Milestones
14.1.3 Clinical Development
14.1.4 Clinical Trials Information
14.1.5 Safety and Efficacy
14.1.6 Product Profile
14.2 NRX-1074 (Apimostinel): Allergen
14.2.1 Drug Description
14.2.2 Regulatory Milestones
14.2.3 Clinical Development
14.2.4 Clinical Trials Information
14.2.5 Product Profile
15 Major Depressive Disorder: Seven Major Market Analysis
15.1 Key Findings
15.2 Market Size of Major Depressive Disorder in the 7MM
16 Market Outlook by Country
16.1 The United States: Market Outlook
16.2 United States Market Size
16.2.1 Total Market Size of Major Depressive Disorder by Class in the US
16.2.2 Market Size of Major Depressive Disorder by Emerging therapies in the US
16.3 EU-5: Market Outlook
16.3.1 Germany
16.3.1.1 Total Market size of Major Depressive Disorder by Class
16.3.1.2 Market Size of Major Depressive Disorder by Emerging therapies in Germany
16.3.2 France
16.3.2.1 Total Market size of Major Depressive Disorder by Class
16.3.2.2 Market Size of Major Depressive Disorder by Emerging therapies in France
16.3.3 Italy
16.3.3.1 Total Market size of Major Depressive Disorder by Class
16.3.3.2 Market Size of Major Depressive Disorder by Emerging therapies in Italy
16.3.4 Spain
16.3.4.1 Total Market size of Major Depressive Disorder by Class
16.3.4.2 Market Size of Major Depressive Disorder by Emerging therapies in Spain
16.3.5 United Kingdom
16.3.5.1 Total Market size of Major Depressive Disorder by Class
16.3.5.2 Market Size of Major Depressive Disorder by Emerging therapies in the UK
16.4 Japan: Market Outlook
16.4.1 Total Market size of Major Depressive Disorder by Class
16.4.2 Market Size of Major Depressive Disorder by Therapies in Japan
17 Market Drivers
18 Market Barriers
19 SWOT Analysis
20 Unmet Needs
21 Market Access
22 Appendix
22.1 Bibliography
22.2 Report Methodology
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/